Benign cyclic breast lumpiness and tenderness — extremely common; reassurance after exclusion of malignancy.
Also known as: fibrocystic breast disease, fibrocystic changes, breast cysts, benign breast disease
Overview
Constellation of benign, hormonally responsive changes in the breast — stromal fibrosis, cyst formation, ductal hyperplasia, and apocrine metaplasia — producing nodularity and cyclic discomfort. No longer considered a 'disease.'
Epidemiology
Most common benign breast condition; affects ~50-60% of reproductive-age women. Peak incidence ages 30-50. Usually subsides after menopause unless on hormone therapy.
Try two board-style Fibrocystic Breast Changes questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1ReproductiveMedium
A 34-year-old woman presents with bilateral breast tenderness and lumpiness that she notices most in the upper outer quadrants. The discomfort worsens in the week before her menstrual period and improves once bleeding begins. On examination, both breasts have a diffuse, ropy, cobblestone texture with a few tender areas; she has no dominant fixed mass, skin or nipple changes, nipple discharge, or axillary lymphadenopathy. The nodularity is less prominent when she is re-examined on day 7 of her cycle. Which of the following is the most likely diagnosis?
AInvasive lobular cancer
BBreast fibroadenoma
CPhyllodes neoplasm
DFibrocystic changes
ESolitary breast cyst
Reveal answer & full explanation
Correct answer: D — Fibrocystic changes
AInvasive lobular cancer
BBreast fibroadenoma
CPhyllodes neoplasm
DFibrocystic changes✓
ESolitary breast cyst
Why Fibrocystic changes is correct
The hallmark is bilateral, diffuse nodularity (classic "cobblestone" or ropy texture), most prominent in the upper outer quadrants, with cyclic mastalgia that peaks premenstrually and eases with menses.
Changes reflect an exaggerated cyclic response to ovarian estrogen and progesterone; they fluctuate with the cycle, so re-examination in days 5-10 (when changes are minimal) helps distinguish them from a true dominant mass.
Absence of a fixed mass, skin/nipple changes, bloody discharge, and lymphadenopathy is reassuring; this is the most common benign breast condition in reproductive-age women.
Why the others are wrong
Breast fibroadenoma — a discrete, mobile, rubbery, well-circumscribed mass in younger women, not diffuse bilateral cyclic nodularity.
Solitary breast cyst — typically a single round, smooth, sometimes tender mass that is anechoic on ultrasound; presents as a discrete lesion rather than diffuse cobblestone change.
Phyllodes neoplasm — a rapidly enlarging firm unilateral mass spanning a benign-to-malignant spectrum, not painful bilateral cyclic lumpiness.
Invasive lobular cancer — invasive lobular carcinoma classically presents as a vague area of thickening rather than a discrete lump, and the upper outer quadrant is the most common site for breast cancer, but malignant thickening persists and does not wax and wane with the cycle; bilateral premenstrual tenderness with nodularity that softens on day-7 re-examination points to a hormonally responsive benign process.
Question 2ReproductiveEasy
A 34-year-old woman reports several years of bilateral breast lumpiness and tenderness that worsens in the week before each menstrual period and eases once menses begin. On exam there is diffuse, cobblestone nodularity in both upper outer quadrants and a few mildly tender areas, with no dominant mass, skin or nipple changes, or lymphadenopathy. Targeted ultrasound shows scattered simple anechoic cysts and no suspicious solid lesions. Which of the following is the most appropriate initial management?
AReassurance and NSAIDs for symptom relief
BUltrasound-guided aspiration of the cysts
COral tamoxifen for mastalgia suppression
DExcisional biopsy of the nodular tissue
ECombined oral contraceptive pills for pain
Reveal answer & full explanation
Correct answer: A — Reassurance and NSAIDs for symptom relief
AReassurance and NSAIDs for symptom relief✓
BUltrasound-guided aspiration of the cysts
COral tamoxifen for mastalgia suppression
DExcisional biopsy of the nodular tissue
ECombined oral contraceptive pills for pain
Why Reassurance and NSAIDs for symptom relief is correct
This is classic fibrocystic breast change: bilateral, diffuse, cyclic nodularity and mastalgia that tracks the menstrual cycle, with a benign exam and benign imaging (simple anechoic cysts, no suspicious solid lesion).
Once malignancy is excluded by exam and ultrasound, first-line management is reassurance plus supportive measures (a well-fitted supportive bra, warm or cool compresses) and oral or topical NSAIDs for mastalgia.
Fibrocystic changes are a benign, hormonally responsive condition and do not themselves raise breast-cancer risk, so conservative symptom-directed care is appropriate before escalating.
Why the others are wrong
Combined oral contraceptive pills for pain — starting a combined OCP is not a proven treatment for mastalgia (ACOG); for a patient already on combined hormonal contraception, continuous dosing (skipping the hormone-free week) may help, but hormonal manipulation is never the first step.
Oral tamoxifen for mastalgia suppression — an off-label option (danazol is the only FDA-approved agent) reserved for severe, refractory mastalgia after supportive care fails; its side-effect profile makes it inappropriate initially.
Excisional biopsy of the nodular tissue — unnecessary when the exam is diffusely benign and imaging shows only simple cysts; sampling is reserved for a discrete suspicious mass, a recurrent or complex cyst, bloody aspirate, or a residual mass after aspiration.
Ultrasound-guided aspiration of the cysts — draining the cysts seems logical once ultrasound shows them, but simple cysts are benign and need no intervention unless one is large, painful, or palpable as a dominant mass; aspirating scattered cysts would not relieve diffuse cyclic mastalgia.
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Fibrocystic Breast Changes outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Caffeine and methylxanthine intake (controversial)
Family history
Pathophysiology
Exaggerated cyclic response to ovarian estrogen and progesterone produces stromal proliferation, lobular hyperplasia, and accumulation of fluid in obstructed terminal ductal lobular units → microcyst and macrocyst formation. Most lesions confer no increased cancer risk; atypical hyperplasia (atypical ductal or lobular hyperplasia) does (~4-5x).
Clinical presentation
Symptoms
Bilateral diffuse breast lumpiness, often most prominent in upper outer quadrants
Cyclic breast pain (mastalgia) worse premenstrually, relieved with menses
Palpable cysts that may fluctuate in size with cycle
Generally NOT associated with bloody nipple discharge
Signs / physical exam
Diffuse nodularity, 'cobblestone' texture
Tender areas, especially premenstrually
Discrete cysts may be palpable
No skin or nipple changes; no lymphadenopathy
Differential diagnosis
Breast cancer — Persistent, fixed, irregular mass with skin/nipple changes; imaging and biopsy
Fibroadenoma — Discrete mobile rubbery mass in younger women; well-circumscribed on ultrasound
Simple cyst — Round, anechoic on ultrasound; can aspirate
Cyclic mastalgia (isolated) — Bilateral premenstrual breast pain WITHOUT lumpiness or nodularity on exam; may be triggered or worsened by exogenous hormones (e.g., recently starting a combined OCP or hormone therapy); clinical diagnosis; same conservative management
Diagnostic workup
Imaging
Clinical breast exam at multiple cycle points to distinguish cyclic changes from persistent mass
Ultrasound — first-line for women <30 or pregnant; characterizes cysts; simple cyst = anechoic, circumscribed round/oval, thin or imperceptible wall, posterior acoustic enhancement, no solid component (BI-RADS 2, benign, no further workup)
Mammography — for women ≥30 with palpable mass
Cyst management by BI-RADS: simple cyst (BI-RADS 2) → routine follow-up, aspirate only if symptomatic; complicated cyst with low-level internal echoes (BI-RADS 3) → aspiration or short-interval imaging follow-up; complex cystic-solid mass (BI-RADS 4-5) → core needle biopsy, not aspiration. After aspiration: non-bloody fluid with complete resolution → discard; bloody fluid or residual mass → image-guided biopsy or excision
Core needle biopsy for solid lesions or recurrent/complex cysts
Diagnostic algorithm
Feature
Fibrocystic Changes
Fibroadenoma
Breast Cyst
Breast Cancer
Age
30-50
15-35
35-50
>40 (usually)
Number / laterality
Multiple, bilateral
Single (sometimes multiple)
Single or multiple
Usually single
Texture
Lumpy, nodular
Firm, rubbery, mobile
Smooth, fluctuant
Hard, fixed, irregular
Cyclic change
Yes (tender premenstrually)
Minimal
Mild
No
Imaging
Heterogeneous, cysts
Well-circumscribed solid
Anechoic, posterior enhancement
Spiculated mass, calcifications
Management
Reassurance, supportive
Observation or excision
Aspiration if symptomatic
Biopsy → oncologic treatment
Distinguishing benign and malignant breast findings.
Reduction in caffeine, dietary fat (modest, inconsistent evidence)
Second-line / adjunct
If already on combined hormonal contraception, continuous dosing (skipping the hormone-free week) may help; starting a COC is not a proven mastalgia treatment. On postmenopausal hormone therapy: lower the estrogen dose or stop it
Danazol (the only FDA-approved drug for mastalgia; androgenic, teratogenic) or tamoxifen 10 mg/day (off-label) — severe refractory mastalgia only, usually for 3-6 months
Evening primrose oil — no proven benefit over placebo in meta-analysis
Cyst aspiration for symptomatic relief
Complications
Patient anxiety from frequent self-detected lumps
Recurrent cyst formation
Coexistence with malignancy (changes do not protect against cancer)
Atypical hyperplasia subset confers increased breast cancer risk (~4x)
PANCE pearls
Nonproliferative fibrocystic change (the usual finding) does NOT increase breast cancer risk; proliferative change without atypia (e.g., florid usual hyperplasia, sclerosing adenosis) raises it slightly (~1.5-2x); atypical ductal or lobular hyperplasia raises it ~4x.
Cyst aspiration is both diagnostic and therapeutic — clear fluid that does not recur requires no further workup.
Bloody fluid from a cyst, residual mass after aspiration, or rapid recurrence → biopsy.
Cyclic mastalgia is much more common than continuous mastalgia; the latter warrants more thorough evaluation.
Reassure patients that lumpiness varies with cycle — best to re-examine in days 5-10 of cycle when changes are minimal.
References
ACOG PB 164 — ACOG Practice Bulletin No. 164: Diagnosis and Management of Benign Breast Disorders. Obstet Gynecol 2016;127(6):e141-e156
ACR BI-RADS 2013 — ACR BI-RADS Atlas: Breast Imaging Reporting and Data System, 5th ed. Reston (VA): American College of Radiology; 2013
Practice Reproductive questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.